MARKET

FGEN

FGEN

FibroGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.11
+0.01
+0.02%
Closed 16:00 08/13 EDT
OPEN
45.11
PREV CLOSE
45.10
HIGH
46.51
LOW
44.73
VOLUME
514.88K
TURNOVER
--
52 WEEK HIGH
48.95
52 WEEK LOW
22.65
MARKET CAP
4.08B
P/E (TTM)
-12.7332
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FGEN stock price target is 60.88 with a high estimate of 84.00 and a low estimate of 44.00.

EPS

FGEN News

More
FibroGen Announces First Patient Enrolled In Pamrevlumab Phase 3 Clinical Trial In Patients With Duchenne Muscular Dystrophy
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab orplacebo in combination
Benzinga · 2d ago
FibroGen EPS misses by $0.39, misses on revenue
FibroGen (NASDAQ:FGEN): Q2 GAAP EPS of -$0.95 misses by $0.39. Revenue of $42.89M (-77.6% Y/Y) misses by $5.4M. Press Release
seekingalpha · 08/07 01:40
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
FibroGen to Report Second Quarter 2020 Financial Results
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00
GlobeNewswire · 07/23 11:00
Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/17 19:31
FibroGen Begins Phase II Study for Acute Coronavirus in US
Zacks · 06/24 17:00
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
GuruFocus.com · 06/23 21:05
FibroGen enrolls first patient in pamrevlumab trial for COVID-19
Seeking Alpha - Article · 06/23 13:05

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About FGEN

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
More

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.